Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease

Atherosclerosis

Volumn 154, Issue 2, 2001, Pages 455-461

  Spósito, Andrei C ^a   Maranhão, Raul C ^a   Vinagre, Carmen G C ^a   Santos, Raul D ^a   Ramires, Jose Antonio F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Disease; Drugs; Heart

Indexed keywords

CARBON 14; CHOLESTEROL OLEATE; ETOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRICEROL; TRIOLEIN; TRITIUM;

ADULT; AGED; ARTICLE; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG DETERMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; EMULSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; CHYLOMICRONS; CLOFIBRIC ACID; CORONARY DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; EMULSIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LIPOLYSIS; MALE; MIDDLE AGED; PROGNOSIS; TRIGLYCERIDES;

EID: 0035129158     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00491-3     Document Type: Article

References (43)

1. Formation and metabolism of chylomicrons
2. A specific apoprotein activator for lipoprotein lipase
3. Triglyceride lipases and atherosclerosis
4. High-density lipoprotein cholesterol, plasma triglyceride, and coronary heart disease: Pathophysiology and management
5. Lipoprotein and receptor interactions in vivo
6. Plasma kinetics of a chylomicron-like emulsion in patients with coronary artery disease
7. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: Case control study over 3 years
8. Postprandial lipoproteins and progression of coronary atherosclerosis
9. Pharmacokinetics and hypolipidemic activity of clofibrate-nicotinic acid combinations in rats
10. Effect of combined clofibrate-nicotinic acid treatment in ischemic heart disease
11. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid
12. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid
13. Influence of etofibrate on low density lipoprotein metabolism
14. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipidemic individuals
15. Gemfibrozil reduces postprandial lipemia in non-insulino-dependent diabetes mellitus
16. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome
17. Treatment of primary mixed hyperlipidemia with etophylline clofibrate: Effects on lipoprotein-modifying enzymes, postprandial lipoprotein metabolism, and lipoprotein distribution and composition
18. Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia
19. Postprandial lipemia, fenofibrate and coronary artery disease
20. Post-prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment
21. Estimation of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge
22. Radiation protection
23. Accumulation of large very low density lipoprotein in plasma during intravenous infusion of a chylomicron-like triglyceride emulsion reflects competition for a common lipolytic pathway
24. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans
25. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters
26. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease
27. Abnormal postprandial apolipoprotein B-48 and triglyceride responses in normolipidemic women with greater than 70% stenotic coronary artery disease: A case-control study
28. Metabolism of protein-free lipid emulsion models of chylomicrons in rats
29. Effects of cholesterol content on the metabolism of protein-free emulsion models of lipoproteins
30. Competition between chylomicrons and their remnants for plasma removal: A study with artificial emulsion models of chylomicrons
31. Clearance from plasma of triacylglycerol and cholesteryl ester after intravenous injection of chylomicron-like lipid emulsions in rats and man
32. Intravenous lipid emulsions: Removal mechanisms as compared to chylomicrons
33. Simultaneous measurements of chylomicron and remnant removal using a doubly labeled artificial lipid emulsion: Studies in normolipidemic and hyperlipidemic subjects
34. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men
35. Adenosine 5′-diphosphate as a factor in platelet aggregation induced by human plasma remnant lipoproteins
36. Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma
37. Remnants of chylomicron and very low density lipoprotein impair endothelium-dependent vasorelaxation
38. Impaired endothelium-dependent acetylcholine-induced coronary artery relaxation in patients with high serum remnant lipoprotein particles
39. Uptake of chylomicron remnants causes cholesterol accumulation in cultured human arterial smooth muscle cells
40. Chylomicrons or their remnants penetrate rabbit thoracic aorta as efficiently as do smaller macromolecules, including low-density lipoprotein, high-density lipoprotein, and albumin
41. Niacin accelerates intracellular apo B degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells
42. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging
43. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: A potential physiologic basis for their mode of action